Simlandi Kit
Product Images NDC 51759-274

Product Visual Gallery

This gallery contains 21 technical images submitted to the FDA as part of the official labeling for Simlandi (NDC 51759-274). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Teva Pharmaceuticals Usa, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Carton1pk (Simlandi Carton 1pk 15)

Simlandi (adalimumab-ryvk) Injection 40 mg/0.4 mL kit carton for subcutaneous use only. The label shows a single-dose autoinjector with dosage strength and usage instructions. The package is marked Rx only and is labeled by Teva Pharmaceuticals USA, Inc. The kit includes one autoinjector dose tray and accompanying documentation.*

FDA Label Image

Carton2pk (Simlandi Carton 2pk 15)

Simlandi (adalimumab-ryvk) Injection 40 mg/0.4 mL carton label showing a kit for subcutaneous use only containing 2 single-dose autoinjectors. The label includes the Teva Pharmaceuticals USA logo and specifies it is Rx only. The design features product details and dosage information on a predominantly white background with blue, green, and purple accents.*

FDA Label Image

1 (Simlandi Injection Bla761299 1)

A line graph depicting the percentage of ACR20 responders over time (weeks) comparing 40 mg every other week dosing of Simlandi (adalimumab-ryvk) versus placebo. The y-axis shows percent ACR20 responders, and the x-axis shows time in weeks, with the active treatment group showing higher response rates than placebo throughout the 48-week duration.*

FDA Label Image

1 (Simlandi Injection Bla761299 10)

An instructional illustration labeled 'Figure E' showing hands being rinsed under running water from a faucet, demonstrating proper handwashing technique.*

FDA Label Image

1 (Simlandi Injection Bla761299 11)

An illustration showing recommended injection sites for Simlandi (adalimumab-ryvk) on a human body. The highlighted areas include the abdomen around the navel and the front thigh regions. The image is labeled as Figure F.*

FDA Label Image

1 (Simlandi Injection Bla761299 12)

An instructional illustration labeled "Figure G" showing a hand holding a cloth, demonstrating the action of wiping in a circular motion on a surface. The arrows indicate the circular wiping pattern.*

FDA Label Image

1 (Simlandi Injection Bla761299 13)

An illustration showing the Simlandi (adalimumab-ryvk) injection cartridge for subcutaneous use, labeled with strength 40 mg/0.4 mL. The close-up inset highlights the liquid fill level inside the cartridge. The image is from Teva Pharmaceuticals USA, Inc. and appears to demonstrate the injection device and liquid content for the kit dosage form.*

FDA Label Image

1 (Simlandi Injection Bla761299 14)

Illustration showing a hand holding a Simlandi prefilled syringe with the label visible, dispensing the dose into a cartridge or vial held by another hand below. It visually demonstrates the extraction or transfer of medication from the syringe to the smaller container below.*

FDA Label Image

1 (Simlandi Injection Bla761299 15)

An instructional illustration depicting the use of a Simlandi (adalimumab-ryvk) injection kit. It shows a hand holding the injectable device at a 90-degree angle, injecting the medication into the skin of another hand to demonstrate proper injection technique.*

FDA Label Image

1 (Simlandi Injection Bla761299 16)

Illustration showing two steps to use a Simlandi 40 mg/0.4 mL injection pen. Figure K depicts pressing the pen down into the skin to hear the first click, followed by waiting up to 10 seconds. Figure L shows pressing the pen further to hear the second click, indicating completion of the injection process.*

FDA Label Image

1 (Simlandi Injection Bla761299 17)

Instructional illustration depicting the proper use of Simlandi (adalimumab-ryvk) 40 mg/0.4 mL autoinjector kit by Teva Pharmaceuticals USA, Inc. The image shows a hand holding the autoinjector with an upward arrow indicating the injection direction, and a second image demonstrating the autoinjector being applied to the skin, labeled as Figure M.*

FDA Label Image

1 (Simlandi Injection Bla761299 18)

An instructional illustration showing a hand disposing of a used Simlandi (adalimumab-ryvk) auto-injector pen into a red sharps disposal container with a yellow lid. The image indicates proper disposal of the used injection device as part of safe handling instructions.*

FDA Label Image

1 (Simlandi Injection Bla761299 19)

FDA Label Image

1 (Simlandi Injection Bla761299 2)

A line graph comparing the percentage of ASAS 20 response over time in weeks for two groups: placebo (N=107) and adalimumab (N=208). The graph shows an increase in response for adalimumab reaching about 50% by week 26, while placebo response remains lower, around 20%.*

FDA Label Image

1 (Simlandi Injection Bla761299 3)

A line graph illustrating treatment failure rates over 20 months comparing placebo and adalimumab groups. The x-axis represents time in months, and the y-axis shows treatment failure rate percentage. Two curves indicate outcomes for placebo (higher failure rate) and adalimumab (lower failure rate), with associated subject numbers below.*

FDA Label Image

1 (Simlandi Injection Bla761299 4)

A line graph showing treatment failure rate over time in months comparing placebo and adalimumab treatments. The graph includes data points and patient counts at various time intervals up to 18 months.*

FDA Label Image

1 (Simlandi Injection Bla761299 5)

An instructional diagram of a Simlandi (adalimumab-ryvk) kit component, showing a clear cap covering the needle, an orange needle sleeve, an inspection window with partial Simlandi branding and storage instruction, and a gray body grip area featuring a textured pattern. The diagram labels each part for clarity.*

FDA Label Image

1 (Simlandi Injection Bla761299 6)

An illustration labeled Figure A showing a hand placing or inserting a rectangular item into an open compartment or slot, possibly representing the use or handling instructions of a medication kit component.*

FDA Label Image

1 (Simlandi Injection Bla761299 7)

An illustration labeled Figure B showing a clock face with the time interval from 15 to 30 minutes highlighted in red on the right half of the clock. The text "15 to 30 minutes" is centered within the clock face.*

FDA Label Image

1 (Simlandi Injection Bla761299 8)

An instructional diagram labeled Figure C showing the assembly or use of a Simlandi kit containing adalimumab-ryvk. It depicts parts of the kit including a syringe and a component with an expiration date and lot number label, indicating proper orientation and labeling details for use or storage.*

FDA Label Image

1 (Simlandi Injection Bla761299 9)

Illustration depicting components of the Simlandi kit by Teva Pharmaceuticals USA, Inc. It shows a single-use autoinjector labeled Simlandi 40 mg/0.4 mL, an alcohol swab packet, a cotton ball, and a red sharps disposal container. The image likely serves instructional or preparatory use guidance for the kit.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.